source
- FDA requires GLP-1 drug labels to include warning about rare eye diseaseThe FDA has issued a directive to manufacturers of GLP-1 therapies, instructing them to revise product labeling. The label change must highlight an increased risk of a rare ocular condition that c…
- Heron sells assets to CorMedix for $145M upfront, Faeth shares plungeHeron Therapeutics announced it has sold a portfolio of assets to CorMedix for an upfront cash payment of $145 million. The transaction gives CorMedix additional product candidates and expands its…